

ASSOCIATION OF THE BRAIN-DERIVED NEUROTROPHIC FACTOR Val66Met POLYMORPHISM WITH BODY MASS INDEX, FASTING GLUCOSE LEVELS AND LIPID STATUS IN ADOLESCENTS

Vidović V^{1,*}, Maksimović N², Novaković I², Damjanović T², Jekić B², Vidović S¹,
Majkić Singh N³, Stamenković-Radak M⁴, Nikolić D⁵, Marisavljević D⁶

*Corresponding Author: Vanja Vidović, M.Sc., Department of Human Genetics, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina. Tel: +38-765-888-475. Fax: +38-751-215-454. E-mail: vanjatmc@hotmail.com

ABSTRACT

Brain-derived neurotrophic factor (BDNF) has an important role in energy balance. It suppresses food intake, reduces hepatic glucose production and converts white fat into brown fat in adipose tissue, leading to energy dissipation, lowered blood glucose and a lean phenotype. Studies have shown that the single nucleotide polymorphism (SNP) Val66Met within BDNF may be associated with obesity, insulin sensitivity, type 2 diabetes mellitus (T2DM) and dyslipidemia. The objective of the study was to investigate the association of the Val66Met polymorphism with body mass index (BMI), fasting glucose levels and lipid profile in Serbian adolescents. The study included 308 randomly selected healthy adolescents, 153 (49.68%) boys and 155 girls (50.32%), 15 years of age. Data including age, gender, height, weight, lipid profile and fasting glucose were recorded. Genotyping was performed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. No association of this polymorphism was found with BMI and lipid profile. However, significant association was observed between this polymorphism and fasting blood glucose (FBG). Carriers of a Val/Val genotype had significantly higher mean values of fasting glucose level compared to carriers of Val/

Met and Met/Met genotypes ($p = 0.01$). To confirm these results multiple linear regression analysis was performed. Body mass index and gender were taken as covariates. Carriers of the Val/Val genotype had significantly higher levels of FBG ($\beta = -0.152$, $p = 0.02$). A statistically significant association between BMI and glucose level was also observed ($\beta = 0.124$, $p = 0.033$). This polymorphism could be associated with fasting glucose level in Serbian adolescents, thus further research would be of great interest to validate these results.

Keywords: Body mass index (BMI); Brain-derived neurotrophic factor (BDNF); Fasting glucose level; Gene polymorphism; Lipid profile.

INTRODUCTION

Obesity is becoming a major health problem of modern society and affects all socio-economic categories, regardless of age, gender and ethnicity. Adolescent obesity is associated with metabolic, cardiovascular, psychological, orthopedic, neurological, respiratory and other disorders [1,2]. Of these, the most common is metabolic syndrome and type 2 diabetes mellitus (T2DM) [3]. Regarding the research of children and adolescent obesity and metabolic diseases, brain-derived neurotrophic factor (BDNF) is gaining increased interest. Brain-derived neurotrophic factor belongs to the neurotrophin family and plays an important role in neurodevelopment, neuronal survival, differentiation, synaptic plasticity and connectivity in the brain. Its function is reflected on memory formation, learning, mood, cognition and stress response [4]. Brain-derived neurotrophic factor is mainly expressed in the central nervous system, but can pass the blood-brain barrier in both directions, and it circulates systemically [5,6]. Through its receptors, BDNF can exert various effects on non-neuronal cells such as testes, thymus, skin, salivary glands and mammary ducts. Besides these functions,

¹ Department of Human Genetics, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina

² Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

³ Society of Medical Biochemists, Belgrade, Serbia

⁴ Department of Genetics and Evolution, Faculty of Biology, University of Belgrade, Belgrade, Serbia

⁵ Department of Physical Medicine and Rehabilitation, Faculty of Medicine, University of Belgrade, University Children's Hospital, Belgrade, Serbia

⁶ Department of Hematology, Medical Center Beza-nijska Kosa, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

BDNF has an important role in food intake regulation, weight control, glucose homeostasis, energy homeostasis, blood pressure and lipid status [3,5]. Through central pathways involved in appetite regulation and energy expenditure, BDNF suppresses food intake, facilitates glucose uptake in the brain, reduces hepatic glucose production and converts white fat into brown fat in adipose tissue, leading to energy dissipation, lowered blood glucose and a lean phenotype [5].

Studies on rodents reported that peripheral injection of BDNF had hypoglycemic and hypophagic effects on obese hyperglycemic animals but not on normal animals [7]. These findings are referring to anti diabetic and anti obesity effects. The human *BDNF* gene is located on chromosome 11p13-11p14 and it contains 11 exons [8]. Within the *BDNF* gene sequence, several single nucleotide poly-morphisms (SNPs) have so far been investigated and the most commonly analyzed SNP is rs6265 (c.196G>A), which causes the change of valine to methionine at amino acid residue 66 in the pro region of the BDNF protein. The methionine allele is associated with the abnormal intracellular trafficking and packaging of pro-BDNF, and consequently, has an impact on secretion of mature peptide [9]. However, Lang *et al.* [10] found a decreased concentration of serum BDNF in healthy Val/Val subjects compared to Val/Met individuals. It has been observed that in healthy subjects defective intracellular protein signaling might be compensated by constitutive upregulation of peripheral BDNF concentration [10].

Association studies of BDNF Val66Met polymorphism and body mass index (BMI), of healthy children and adolescents have shown contradictory results [3,11,12], while studies of association between the Val66Met polymorphism and glucose level as well as lipid status of children and adolescents are still rare [12]. The aim of this study was to investigate the association of the Val66Met (rs6265) polymorphism with BMI, fasting glucose levels and lipid profiles of healthy adolescents.

MATERIAL AND METHODS

Study Design and Study Population. Subjects enrolled in the study ($n = 308$) were randomly selected school children of both genders, 15 years of age, who participated in the Yugoslav Study of the Precursors of Atherosclerosis in School Children (YUSAD), a prospective multicentric study that lasted from 1989 to 2008. Cross-sectional data used in this study were collected during 2003. Age, gender, height, weight, lipid profile [total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) cholesterol, triglycerides (TG)] and fasting glucose level were recorded during an annual general medical examination performed by pediatricians at 11 pediatric departments of primary health care centers (Čukarica, Palilula, Požarevac, Užice, Kraljevo, Knjaževac,

Bor, Niš, Subotica, Arilje and Despotovac) in Serbia. The children had normal growth and development, without any morbidities (acute inflammatory disease or chronic disease) at the time of examination. Data were collected using standardized questionnaires and clinical examinations (height, body mass). Body mass index was calculated as the participant's weight in kilograms divided by the square of their height in meters. Height was measured without shoes to the nearest of 1 cm. Stadiometer and stretch stature methods were used. Weight was measured wearing light clothes and without shoes to the nearest 0.1 kg using scales precalibrated by the research team. The children were classified in normal weight, overweight (above 85th percentile) and obese (above 97th percentile) groups according to BMI charts published for Serbian children 15 years of age [13]. Type 1 or type 2 diabetes mellitus, genetic syndromes, cerebral palsy, chronic immobility, generalized inflammation, cardiovascular and malignant diseases were criteria for exclusion. Signed informed consent was obtained from each participant's parent or guardian. Siblings and relatives were not included in the study. Study protocol was approved by the Ethics Committee of the Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Genotyping. Molecular-genetic analyses were performed at the Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Genomic DNA was extracted from 5 mL of peripheral blood according to Miller *et al.* [14]. Genotypes of SNP Val66 Met (rs6265) were detected by classic polymerase chain reaction (PCR) followed by restriction fragment length polymorphism (RFLP) analysis. The PCR conditions were: initial denaturation for 5 min. at 95 °C, followed by 35 cycles of 1 min. denaturation at 95 °C, primer annealing for 30 seconds at 55 °C, extension and polymerization for 1 min. at 72 °C, and final extension for 7 min. at 72 °C. The forward primer used in genotyping was F: 5'-ACT CTG GAG AGC GTG AAT GG-3', and reverse primer was R: 5' ACT ACT GAG CAT CAC CCT GGA-3'. Amplified products of 171 bp were digested with *Eco72I* restriction enzyme for 2 hours at 37 °C. The amplified fragments were analyzed on 8.0% polyacrylamide gel electrophoresis (PAGE). After electrophoretic separation, depending on the genotype, the different fragment lengths were notable. Fragments of 171 bp corresponded to genotype AA, while fragments of 99 and 72 bp were seen in genotype GG [15].

Biochemical Analysis. Each participant fasted for 12 hours before blood sample collection. Levels of serum glucose, total cholesterol, HDL-C and TG were measured as described previously, LDL-C concentrations in samples were calculated using Friedewald's equation [13].

Statistical Analyses. For statistical analyses, the Statistical Package for Social Science (SPSS) version 17 (SPSS Inc., Chicago, IL, USA) was used. Quantitative

variables were expressed as mean ± SD. The association of genotypes and BMI, fasting glucose level and serum lipid levels was tested by Student's *t*-test or Mann-Whitney test depending on the variable distribution. In order to evaluate the association of fasting blood glucose (FBG) levels and *BDNF* genotypes with gender and BMI as covariates, mul-tivariate linear regression analysis was performed.

RESULTS

Of 308 adolescents included in the study, 153 (49.68%) were boys and 155 were girls (50.32%). Of the boys, 26 (17.8%) were overweight and 20 (13.7%) were obese. In the group of girls, 29 (18.7%) were overweight and 17 were obese (11.0%). The mean values and ranges of analyzed parameters depending on the gender are presented in Table 1. Based on the guidelines for cardiovascular health and risk reduction in children and adolescents [16] we observed that in the adolescents included in our

study there were 48 (15.58%) and 16 (10.46%) boys and 32 (20.64%) girls with high levels of total cholesterol (TC) and LDL-C (TC level higher than 5.2 mmol/L and LDL-C level higher than 3.35 mmol/L), while 13 adolescents (4.22%), eight boys (5.23%) and five girls (3.22R) had HDL-C lower than 0.9 mmol/L. Moreover, 25 adolescents (8.12%), 13 boys (8.50%) and 12 girls (7.74%) had high levels of TG (higher than 1.7 mmol/L). There was statistically significant difference in total cholesterol levels between the groups of boys and girls (*p* = 0.001), meaning that girls had significantly higher mean values of total cholesterol. Statistically significant difference was not observed in the other analyzed parameters.

Frequencies of Genotypes and Alleles of rs6265 (Table 2). The distribution of genotypes were in Hardy-Weinberg equilibrium. As only three samples were genotyped as AA, GA and AA genotypes were grouped for further analyses.

The mean values of analyzed parameters depending of the *BDNF* genotypes are presented in Table 3. Our analysis

Table 1. Mean values and range of analyzed parameters depending on gender.

Parameters	Total (n = 308) (range)	Boys (n = 153)	Girls (n = 155)	p Value
BMI (kg/m ²)	22.03±4.25 (13.8-43.72)	21.77±4.22	22.29±4.29	0.405
FBG (mmol/L)	4.68±0.63 (2.43-6.30)	4.75±0.59	4.61±0.66	0.660
TG (mmol/L)	0.98±0.55 (0.32-2.54)	0.97±0.62	0.99±0.47	0.891
TC (mmol/L)	4.35±0.86 (2.64-6.70)	4.18±0.76	4.51±0.93	0.001
HDL-C (mmol/L)	1.41±0.40 (0.28-2.63)	1.37±0.42	1.45±0.38	0.159
LDL-C (mmol/L)	2.47±0.86 (0.53-4.82)	2.39±0.81	2.55±0.90	0.057

BMI: body mass index; FBG: fasting blood glucose; TG: triglycerides; TC: statistically significant total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.

Table 2. Frequencies of *BDNF* genotypes and alleles.

<i>BDNF</i> rs6265 Genotypes	Frequency n (%)	Alleles	Frequencies (%)
GG	202 (65.6)	G	0.82
GA	103 (33.4)	–	–
AA	3 (1.0)	A	0.18

BDNF: brain-derived neurotrophic factor.

Table 3. Mean values of analyzed parameters by *BDNF* rs6265 genotype (mean±SD).

Parameters	Genotype	Total	p Value	Boys	p Value	Girls	p Value
BMI (kg/m ²)	GG	22.17±4.37	0.378	21.79±4.14	0.715	22.54±4.57	0.367
	GA+AA	21.76±3.82		21.74±4.40		21.80±3.67	
FBG (mmol/L)	GG	4.74±0.66	0.010	4.79±0.62	0.302	4.70±0.70	0.023
	GA+AA	4.56±0.56		4.68±0.55		4.43±0.55	
TG (mmol/L)	GG	0.99±0.52	0.599	0.96±0.54	0.679	1.02±0.52	0.624
	GA+AA	0.97±0.59		0.99±0.75		0.95±0.36	
TC (mmol/L)	GG	4.36±0.86	0.931	4.18±0.74	0.848	4.53±0.93	0.756
	GA+AA	4.34±0.88		4.20±0.82		4.48±0.94	
HDL-C (mmol/L)	GG	1.42±0.42	0.484	1.34±0.34	0.580	1.45±0.41	0.659
	GA+AA	1.44±0.44		1.42±0.53		1.48±0.33	
LDL-C (mmol/L)	GG	2.47±0.87	0.911	2.38±0.85	0.879	2.55±0.93	0.873
	GA+AA	2.48±0.84		2.40±0.80		2.57±0.84	

BDNF: brain-derived neurotrophic factor; BMI: body mass index; FBG: Statistically significant fasting blood glucose; TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.

showed that mean values of FBG were significantly higher in carriers of the GG genotype compared to carriers of the GA and AA genotypes ($p = 0.01$). To confirm these results, multiple linear regression analysis was performed. Body mass index and gender were taken as covariates. Carriers of the GG genotype had significantly higher levels of FBG ($\beta = -0.152, p = 0.02$). Statistically significant association between BMI and glucose level was also observed ($\beta = 0.124, p = 0.033$). There was no statistically significant difference in BMI and lipid profile of adolescents depending on their rs6265 polymorphism genotype.

DISCUSSION

The aim of this study was to investigate the association between the Val66Met polymorphism of *BDNF* and BMI, FBG, TG, TC, HDL-C and LDL-C in 308 15-year-old school children. In previous studies, this polymorphism was linked to obesity and metabolic syndrome [3,17,18]. Some studies demonstrated that BDNF may suppress food intake, insulin resistance and maintain glucose homeostasis [5,19]. In our study, association of the Val66Met polymorphism with BMI was not found. A previous study conducted by Friedel *et al.* [20] also did not find significant association between the analyzed polymorphism and obesity in a group of adolescents who were carriers of the methionine variant. However, a study conducted on Chinese children [21] refers to the valine allele as a risk allele associated with higher BMI and obesity in children, which is in agreement with the results obtained in a group of 2131 children, age 6-18, who reported that methionine allele carriers had significantly lower BMI [12]. Another study also revealed that, in healthy Caucasians, the Met/Met genotype had a protective effect against obesity [4].

However, there are studies with contradictory results. Healthy Croatian children and adolescents carrying one or two methionine alleles tend to have higher BMI and are prone to obesity [3]. Furthermore, a Mexican study in a pediatric population showed a significant association between the Met/Met genotype and obesity [11].

In our study, we did not observe a statistically significant association between the *BDNF* polymorphism and lipid profile of adolescents. Association of the Val66Met polymorphism and lipid parameters [12] in their group of children and adolescent was also not found. However, Peng *et al.* [5], noted a correlation between *BDNF* Val66 Met and lipid profiles where the methionine variant was linked to higher triglyceride levels, but lower HDL-C levels in the group of long-lived individuals.

The major finding of our study is the association of the Val66Met polymorphism and levels of FBG. Statistical analysis revealed that carriers of the Val/Val genotype

had significantly higher mean values of FBG compared to carriers of the Val/Met or Met/Met genotypes ($p = 0.01$). Kalenda *et al.* [12] found that FBG levels were not associated with the Val66Met genotype, but they did find lower postprandial glucose levels in a post-pubertal group of children who were carriers of the methionine allele. It has been observed that BDNF levels are related to glucose concentrations [22]. Furthermore, normal weight, regular exercise, nonstressed, and nonsmoking middle aged individuals with Val/Met and Met/Met alleles were less likely to develop glucose intolerance and T2DM [23]. Minelli *et al.* [24], and Lang *et al.* [10] have shown the association of the Val/Val genotype with low levels of serum BDNF in healthy subjects. This could explain the observed association between the Val/Val genotype and higher glucose level in our study. However, the association of the Val66 Met genotype with BDNF serum or plasma levels in children, adolescents or adults, was not confirmed in other studies [12,25,26]. Peripheral level of BDNF depends on numerous factors such as age, gender, hormonal status, circadian variation, platelet count, diet and exercise [12,27,28]. This complex mechanism of regulation of BDNF levels could be the reason for the contradictory results regarding the association of the Val66Met polymorphism with peripheral BDNF levels.

In conclusion, we did find that carriers of the Val/Val genotype had statistically significant higher mean values of FBG compared to carriers of the Val/Met or Met/Met genotype. However, the results are still contradictory and it would be of great interest to conduct a study on a larger sample size and to include other *BDNF* gene polymorphisms.

ACKNOWLEDGMENTS

We would like to thank all of the participants in this study for sample collection.

Declaration of Interest. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Funding. This study was supported by the Serbian Ministry of Education, Science and Technological development [Grant 175091].

REFERENCES

1. Sabin MA, Clemens SL, Saffery R, Mccallum Z, Campbell MW, Kiess W, *et al.* New directions in childhood obesity research: How a comprehensive biorepository will allow better prediction of outcomes. *BMC Med Res Methodol.* 2010; 10: 100.

2. Zanquetta MM, Corrêa-Giannella ML, Monteiro MB, Villares SM. Body weight, metabolism and clock genes. *Diabetol Metab Syndr*. 2010; 2: 53.
3. Skledar M, Nikolac M, Dodig-Curkovic K, Curkovic M, Borovecki F, Pivac N. Association between brain-derived neurotrophic factor Val66Met and obesity in children and adolescents. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012; 36(1): 136-140.
4. Sustar A, Nikolac Perkovic M, Nedic Erjavec G, Svob Strac D, Pivac N. A protective effect of the BDNF Met/Met genotype in obesity in healthy Caucasian subjects but not in patients with coronary heart disease. *Eur Rev Med Pharmacol Sci*. 2016; 20(16): 3417-3426.
5. Peng J-H, Liu C-W, Pan S-L, Wu H-Y, Liang Q-H, Gan R-J, *et al*. Potential unfavorable impacts of BDNF Val66Met polymorphisms on metabolic risks in average population in a longevous area. *BMC Geriatr*. 2017; 17(1): 4.
6. Golden E, Emiliano A, Maudsley S, Windham BG, Carlson OD, Egan JM, *et al*. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: Data from the Baltimore Longitudinal Study of Aging. *PLoS One*. 2010; 5(4): e10099.
7. Eyileten C, Kaplon-Cieslicka A, Mirowska-Guzel D, Malek L, Postula M. Antidiabetic effect of brain-derived neurotrophic factor and its association with inflammation in type 2 diabetes mellitus. *J Diabetes Res*. 2017; 2017: 2823671.
8. Rosas-Vargas H, Martínez-Ezquerro JD, Bienvenu T. Brain-derived neurotrophic factor, food intake regulation, and obesity. *Arch Med Res*. 2011; 42(6): 482-494.
9. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, *et al*. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell*. 2003; 112(2): 257-269.
10. Lang UE, Hellweg R, Sander T, Gallinat J. The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. *Mol Psychiatry*. 2009; 14(2): 120-122.
11. Martínez-Ezquerro JD, Rendón-Macías ME, Zamora-Mendoza GS, Serrano-Meneses JC, Rosales-Rodriguez B, Escalante-Bautista D, *et al*. Association between the brain-derived neurotrophic factor Val66Met polymorphism and overweight/obesity in Mexican pediatric population. *Arch Med Res*. 2017; 48(7): 599-608.
12. Kalenda A, Landgraf K, Löffler D, Kovacs P, Kiess W, Körner A. The BDNF Val66Met polymorphism is associated with lower BMI, lower postprandial glucose levels and elevated carbohydrate intake in children and adolescents. *Pediatr Obes*. 2017; 13(3): 159-167.
13. Majkić-Singh N, Janković O, Ignjatović S, Obradović I (2006) Trendovi u nalazima lipidnih frakcija u JU-SAD studiji. In: Nedeljković S, Vukotić M, Editors. *Jugoslavenska Studija Prekursora Ateroskleroze kod Školske Dece*. Belgrade, Serbia: Centar za Izdavačku, Bibliotečku i Informacionu Delatnost (CIBID), Faculty of Medicine, University of Belgrade, Serbia; 2006: 323-334.
14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*. 1988; 16(3): 1215.
15. Kim JM, Stewart R, Park MS, Kang HJ, Kim SW, Shin IS, *et al*. Associations of BDNF genotype and promoter methylation with acute and long-term stroke outcomes in an East Asian cohort. *PLoS One*. 2012; 7(12): e51280.
16. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. National Heart, Lung and Blood Institute. *Pediatrics*. 2011; 128(5): 213-256.
17. Bonaccorso S, Sodhi M, Li J, Bobo WV, Chen Y, Tumuklu M, *et al*. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. *Bipolar Disord*. 2015; 17(5): 528-535.
18. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, *et al*. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. *Nat Neurosci*. 2003; 6(7): 736-742.
19. Beckers S, Peeters A, Zegers D, Mertens I, Gaal LV, Hul WV. Association of the BDNF Val66Met variation with obesity in women. *Mol Genet Metab*. 2008; 95(1-2): 110-112.
20. Friedel S, Horro FF, Wermter A, Geller F, Dempfle A, Reichwald K, *et al*. Mutation screen of the brain derived neurotrophic factor gene (BDNF): Identification of several genetic variants and association studies in patients with obesity, eating disorders, and attention-deficit/hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet*. 2005; 132B(1): 96-99.
21. Zhang M, Zhao X, Xi B, Shen Y, Wu L, Cheng H, *et al*. Impact of obesity-related gene polymorphism on risk of obesity and metabolic disorder in childhood. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2014; 48(9): 776-783.

22. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, *et al.* Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. *Diabetologia*. 2007; 50(2): 431-438.
23. Daily JW, Park S. Interaction of BDNF rs6265 variants and energy and protein intake in the risk for glucose intolerance and type 2 diabetes in middle-aged adults. *Nutrition*. 2017; 33(1): 187-194.
24. Minelli A, Zanardini R, Bonvicini C, Sartori R, Pedrini L, Gennarelli M, *et al.* BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. *Eur Arch Psychiatry Clin Neurosci*. 2011; 261(5): 323-329.
25. Terracciano A, Piras MG, Lobina M, Mulas A, Meirelles O, Sutin AR, *et al.* Genetics of serum BDNF: Meta-analysis of the val66Met and genome-wide association study. *World J Biol Psychiatry*. 2013; 14(8): 583-589.
26. Luykx JJ, Boks MP, Breetvelt EJ, Aukes MF, Strengman E, da Pozzo L, *et al.* BDNF Val66Met homozygosity does not influence plasma BDNF levels in healthy human subjects. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013; 43: 185-187.
27. de Azevedo KPM, de Oliveira Segundo VH, de Medeiros GCBS, de Sousa Mata AN, Garcia DÁ, de Carvalho Leitão JCG, *et al.* Effects of exercise on the levels of BDNF and executive function in adolescents: A protocol for systematic review and meta-analysis. *Medicine (Baltimore)*. 2019; 98(28): e16445.
28. Iughetti L, Casarosa E, Predieri B, Patianna V, Luisi S. Plasma brain-derived neurotrophic factor concentrations in children and adolescents. *Neuropeptides*. 2011; 45(3): 205-211.